Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06203145
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
- Conditions
- AL AmyloidosisAmyloidosis; Systemic
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Jin Lu, MD
- Target Recruit Count
- 41
- Registration Number
- NCT06192979
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 200
- Registration Number
- NCT06189833
- Locations
- 🇬🇷
St Savvas Cancer Hospital, Athens, Greece
🇩🇪Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany
🇦🇹Innsbruck Medical University, Innsbruck, Austria
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06169215
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UCI Health Laguna Hills, Laguna Hills, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- 🇺🇸
University of Alabama at Birmingham - Main /ID# 261434, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Hospital - Phoenix /ID# 263326, Phoenix, Arizona, United States
🇺🇸Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇫🇷
Hôpital NOVO, Pontoise, Val-d'oise, France
🇺🇸Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple MyelomaExtramedullary Multiple MyelomaPrimary Plasma Cell Leukemia
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 54
- Registration Number
- NCT06140966
- Locations
- 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Conditions
- Multiple MyelomaMonoclonal Gammopathy of Renal Significance
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT06083922
- Locations
- 🇺🇸
Tufts Medical Center (Data Collection Only), Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed Remission
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 50
- Registration Number
- NCT06034561
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil
Bortezomib in Patients with Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 22
- Registration Number
- NCT06029998
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.